Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab

References

• Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005;23:1–21.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin-6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619–26.
   PubMedGoogle Scholar
• Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73–6.
   PubMed Web of Science ®Google Scholar
• Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, et al. IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA. 1989;86(19): 7547–51.
   PubMed Web of Science ®Google Scholar
• Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett. 1987;15(3): 249–53.
   PubMed Web of Science ®Google Scholar
• Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141(5):1543–9.
   PubMed Web of Science ®Google Scholar
• Kopf M, Baumann H, Freeer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339–42.
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood.1989;74(4):1360–7.
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion. 1991; 50(2):104–11.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol. 1998;25(2):203–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87(4):483–7.
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851–6.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic- onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617): 998–1006.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22(1):109–15.
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126(4):989–96.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20(3):222–32.
   PubMed Web of Science ®Google Scholar
• Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.
   Web of Science ®Google Scholar
• Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331–9.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19(1):64–8.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Influenza HA vaccine package insert (The research foundation for microbial disease of Osaka University).
   Google Scholar
• Pneumovax 23 (Pneumococcal vaccine polyvalent) package insert, 7999825 (Merck & Co., inc., Whitehouse Station, NJ, USA).
   Google Scholar
• Committee for Proprietary Medicinal Products (CPMP) Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines, 2001, CPMP/EWP/1045/01.
   Google Scholar
• Palmer DF, Coleman MT, Dowdle WR. Advanced laboratory techniques for influenza diagnosis. Public health service. US Department of Health, Education and Welfare. Atlanta: Center for Disease Control; 1975.
   Google Scholar
• Recommendations of the Swedish National Board of Health and Welfare. Pneumococcal Vaccination. http://www.Sos.se/sosfs/1994_ 26/1994_26.htm??May 2002?
   Google Scholar
• Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, Yokota S. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012;22(6):871–6.
   PubMed Web of Science ®Google Scholar
• Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(12):2006–10.
   PubMed Web of Science ®Google Scholar
• Obaro SK, Henderson DC, Monteil M. Immunity to pneumococcal infections. Lancet. 1995;345(894):70–1.
   PubMedGoogle Scholar
• Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: meta-analysis. J Allergy Clin Immunol. 1996;98(1):205–15
   PubMed Web of Science ®Google Scholar
• CDC recommendations of the Advisory Committee on Immunization practices (ACIP). Prevention of pneumococcal Disease 1997/46 (RR-08); 1–24) http://www.cdc.gov/mmwr/pdf/rr/rr4608.pdf (Oct 2013).
   Google Scholar
• Cho Y, Basta S, Chen W, Bennink JR, Yewdell JW. Heat-aggregated noninfectious influenza virus induces a more balanced CD8+- T-lymphocyte immunodominance hierarchy than infectious virus. J Virol. 2003;77(8):4679–84.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Sanders L, Rijkers GT, Zegers BJ. Cell bilology of B lymphocyte activation by polysaccharides. J Infect Dis. 1992; 165(Suppl 1):S71–3.
   Google Scholar